• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Tinea Pedis (Athlete’s Foot)

Article

The 2% preparation of an allylamine antifungal is a new addition to the menu of available topical agents. It has the advantage of once-daily dosing and shorter course of therapy.

A 49-year-old man complained about mild itching and scaling on the foot, particularly at the base of the toes. His nails were intact.

Key points: Physical examination disclosed a classic example of tinea pedis (athlete’s foot). (See related article.) Any topical antifungal agent, used diligently for a long enough time, will clear this.

Treatment: After discussion of various options, the patient elected to apply nafitifine 2% cream once daily for 2 weeks. His rash resolved.

Note: The 2% preparation of an allylamine antifungal is a new addition to the menu of available topical antifungal agents. It has the advantage of once-daily dosing and shorter course of therapy.

Related Content
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Sydney Jennings
February 5th 2025
Article

Your daily dose of the clinical news you may have missed.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD Queen’s University

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Grace Halsey
February 4th 2025
Article

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

Grace Halsey
January 27th 2025
Article

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

© 2025 MJH Life Sciences

All rights reserved.